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A B S T R A C T
Background: Reduced intensity treatment of low-risk febrile neutropenia (FN) in children with cancer is safe
and improves quality of life. Identifying children with low-risk FN using a validated risk stratification strategy
is recommended. This study prospectively validated nine FN clinical decision rules (CDRs) designed to predict
infection or adverse outcome.
Methods: Data were collected on consecutive FN episodes in this multicentre, prospective validation study.
The reproducibility and discriminatory ability of each CDR in the validation cohort was compared to the deri-
vation dataset and details of missed outcomes were reported.
Findings: There were 858 FN episodes in 462 patients from eight hospitals included. Bacteraemia occurred in 111
(12¢9%) and a non-bacteraemiamicrobiological documented infection in 185 (21¢6%). Eight CDRs exhibited repro-
ducibility and sensitivity ranged from 64% to 96%. Rules that had >85% sensitivity in predicting outcomes classi-
fied few patients (<20%) as low risk. For three CDRs predicting a composite outcome of any bacterial or viral
infection, the sensitivity and discriminatory ability improved for prediction of bacterial infection alone. Across all
CDRs designed to be implemented at FN presentation, the sensitivity improved at day 2 assessment.
Interpretation: While reproducibility was observed in eight out of the nine CDRs, no rule perfectly differenti-
ated between children with FN at high or low risk of infection. This is in keeping with other validation studies
and highlights the need for additional safeguards against missed infections or adverse outcomes before
implementation can be considered.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Children with cancer and febrile neutropenia (FN) are a heteroge-
neous group with varying risk of infection. This heterogeneity is not
always reflected in management, with many clinicians and centres
treating all patients with intravenous antibiotics, irrespective of under-
lying risk [1,2]. This is contrary to international paediatric FN guideline
recommendations that centres ‘adopt a validated risk stratification
strategy and incorporate it into practice [3]. Such a strategy might facili-
tate reduced-intensity treatment within the first 24 h with oral antibiot-
ics or home-based management in patients identified as low risk [4].
The benefits of this include improved quality of life, decreased exposure
to nosocomial infections and reduced health costs [5,6].
As many as 27 paediatric FN clinical decision rules (CDRs), designed
to stratify patients into low and high risk of severe infection or medical
complication, have been derived [7-13]. However, ongoing uncertainty
remains as to the most safe and effective rule [7]. Before a CDR can be
used it must undergo validation to determine applicability in a new
population and time period. This is especially important for CDRs
designed to predict children with low-risk FN and trigger reduced-
intensity treatment. As CDR performance in validation and implementa-
tion is usually lower than in derivation, a realistic expectation of a rules
predictive ability may ensure appropriate safeguards are in place to pro-
tect against missed infections or adverse events [7].
Across Australia, home-based or reduced intensity treatment of chil-
dren with FN identified as low-risk of infection or adverse outcome is
not standard of care [2]. Availability of validated CDRs to assist in the
identification of these patients has the potential to increase the uptake
of dedicated low-risk FN care pathways. The objective of this study was
to prospectively validate nine CDRs that predict infection or adverse
outcome in children with solid-organ cancer or leukaemia. Performance
of the CDRs at day 2 was also assessed.
2. Methods
This was a prospective, multicentre, non-interventional study (Aus-
tralian New Zealand Clinical Trials Registry 12616001440415). All eight
Australian tertiary paediatric hospitals participated. Children with
solid-organ cancer or leukaemia on active treatment and who were
admitted to hospital or presented to the emergency, outpatient or day-
chemotherapy departments with fever or clinical instability were eligi-
ble for inclusion. Fever was defined as a temperature 38°C and neu-
tropenia was defined as an absolute neutrophil count (ANC) <1000/
mm3. Children with hematopoietic stem cell transplant (HSCT) within
three months or receiving treatment antibiotics were excluded. Multi-
ple, discrete FN episodes per patient were allowed. Methodology and
reporting of results followed the Transparent Reporting of a multivari-
able prediction model for Individual Prognosis Or Diagnosis statement
(TRIPOD) [14].
Demographic, FN episode and outcome data were prospectively col-
lected by the site research assistant (RA) from entirely electronic (1 site)
and combined electronic and paper-based records (7 sites), and entered
into REDCap. The RA was blinded to the CDR variables and outcome
definitions and data accuracy was verified by the project manager and
site investigators (oncology or infectious diseases physician).
Clinical variables were collected at two time points: presentation
(day 1), which was 04 h from hospital presentation for outpatient-
onset FN and from fever onset for inpatient-onset FN, and day 2. Data
for day 2 were taken between 0900 and 1100am the morning follow-
ing admission to replicate the period where clinical ward-round deci-
sions are made. Infection outcomes were from clinical symptoms or
microbiological samples taken 48 h of FN onset. Other outcome
data were collected at the end of FN episode and on day 30. For epi-
sodes occurring outside ‘office’ hours, data was collected within 72 h.
Study definitions are outlined in Table 1. Other outcomes were
defined according to the derivation studies (Table 2).
Children were managed according to local FN guidelines with
piperacillin-tazobactam used as first-line empiric FN therapy. During
the study period there was a piperacillin-tazobactam shortage across
four sites and local guidelines were modified to include cefepime as
first line at three sites and ceftazidime and flucloxacillin at one site. A
formal low-risk FN pathway was not in use during the study period
and cessation of antibiotics and hospital discharge was typically
Research in context
Evidence before this study
Reduced intensity treatment of low-risk febrile neutropenia (FN)
in childrenwith cancer has been shown to be safe, improve quality
of life and reduce costs of care. International paediatric FN guide-
lines recommend that centres adopt a validated risk stratification
strategy and incorporate it into practice. While as many as 27 pae-
diatric FN clinical rules (CDRs), designed to stratify patients into
low and high risk of severe infection or medical complication,
have been derived ongoing uncertainty remains as to the most
safe and effective rule. This is largely because very few CDRs have
undergone prospective, external validation. We searched PubMed,
with no restrictions on language or publication date, using the
search terms: “febrile neutropenia” AND “clinical decision rule” OR
“risk prediction” AND “validation.” Only ten CDRs have undergone
prospective, external validation, of which six were validated in
multisite studies. These studies were conducted in Europe and
India and no CDRs have been prospectively validated in Australia.
Added value of this study
This is the largest, multicentre prospective validation study of
paediatric FN CDRs published to date and the first time the PIC-
NICC CDR had been prospectively validated. In addition to
assessing reproducibility (sensitivity and specificity) and dis-
criminatory ability (AUC-ROC) we also provide a comprehen-
sive assessment of clinical utility of each rule and report details
of all clinically significant missed outcomes. Performance of
each CDR for the prediction of a ‘likely bacterial infection’ and
the impact of an overnight period of in-hospital observation is
also provided. Although eight out of the nine validated CDRs
were reproducible, overall discriminatory ability at FN presen-
tation was poor. Reassuringly, performance of all CDRs
improved after an overnight period of observation and for three
CDRs sensitivity and discriminatory ability increased for predi-
cation of bacterial infection. The CDR’s with the highest sensi-
tivity tended to classify fewer FN episodes as low-risk.
Implications of all the available evidence
Currently no published paediatric CDR can perfectly predict infec-
tions or adverse outcomes in children presenting with FN. Given
that there have been at least 27 attempts to derive such a rule,
this quest for perfection is unlikely to be achieved using currently
available clinical, radiological and biochemical parameters.
Depending on the desired low-risk management strategy, a num-
ber of the validated CDRs could be incorporated into practice. For
entirely home-based treatment, CDRs with the highest sensitivity
and NPV should be used, while CDRs with lower sensitivity could
be used to select suitable patients for early (<24 h) transfer to
home-based care. However, irrespective of the approach, appro-
priate safe guards such as a period of in-hospital observation,
together with a structured home-based program incorporating
clear recommendations for readmission, remain paramount.
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considered in patients with ANC recovery beyond nadir, negative cul-
tures and at least a 24 h afebrile period.
Microbiological investigations were performed according to site
FN guidelines. Across all sites this included: at least one blood culture
set (all patients) and urine for culture; nasal swab for respiratory
virus PCR; chest X-ray; stool for culture, Clostridioides difficile toxin
assay and viral PCR; and skin or wound swab for culture and viral
PCR (as indicated).
2.1. Identification of CDRs for validation
Twenty-seven potentially relevant studies were identified
[713,19,20]. Of these, nine CDRs were suitable for validation in this
dataset (Table 2) [8,2128]. Insufficient information was collected for
eight, with three incorporating C-reactive protein that is not routinely
used for FN in Australia [9,20,27,2933]. Nine studies only described
individual variables for infection, [1013,3438] and in one, a central
venous catheter (CVC) was used as a predictor of outcome [39]. As CVCs
are present in >95% of paediatric oncology patients in Australia, this
was deemed a priori as non-discriminatory [40].
2.2. Statistical analysis
To assess reproducibility, the sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV) of each CDR
using the pre-defined thresholds and outcomes were calculated and
compared to the derivation datasets.
For the Predicting Infectious ComplicatioNs in Children with Cancer
(PICNICC) rule, previously reported recalibrated PICNICC variables were
used and clinical utility was assessed by dichotomising at  10% chance
of microbiologically defined infection (MDI) [40]. The PICNICC rule was
derived from an individual participant data meta-analysis of 1101 FN
episodes and uses different predictors for type of malignancy and log-
transformed data. Full details of the model, including the original beta
estimates is available elsewhere [8]. The threshold of 10% was derived
from discussion with the collaborating members of the international
PICNICC group. This included a series of clinically active paediatric can-
cer and infectious diseases research physicians, a parent whose child
had undergone treatment for malignancy and who had experienced FN,
and statisticians. It was agreed that up to a 10% risk of MDI would be an
acceptable threshold for classification of low-risk.
For the Rackoff rule that stratified patients into >2 groups, both
the low and intermediate and the intermediate and high-risk groups
were combined for calculation of sensitivity and specificity [26].
Across all CDRs, data were reported separately for all FN episodes
(inpatient and outpatient onset FN) and for outpatient-onset FN only.
To determine the overall discriminatory ability of the CDR’s the
AUC-ROC curve and likelihood ratios were calculated. For the PICNICC
CDR, the scaled Briers score and the calibration slope were also
reported. The scaled Briers score reflects the proportion of incorrectly
assigned episodes, and the calibration slope estimates how precisely
the predicted probability of infection meets the measured values
[41]. Re-estimation of the odds ratios of the individual variables was
made by logistic regression using the same covariates as the original
model. All analyses were done using R version 3.2.0.
To assess clinical utility, the following missed outcomes were
reported: bacteraemia, ICU admission, severe sepsis/septic shock and
death. The ability of the CDRs to predict ‘likely bacterial infection’
and the impact of an overnight period of observation on sensitivity
were also calculated.
The clinical utility of each CDR at day 2was assessed usingmethodol-
ogy described by the Swiss Paediatric Oncology Group (SPOG) [21]. Using
variables collected at presentation, the sensitivity of the rule at day 2
(between 0900 and 1100am) was determined by combining the infor-
mation on episodes with the outcome known at that time with the
results of prediction on the remaining episodes. Clinical utility of the PIC-
NICC CDR at day 2 was further assessed using variables collected on day
2 as previously described [40]. Episodes that had already been shown to
have any of MDI, severe sepsis/septic shock or intensive care unit (ICU)
admission before day 2 assessment were excluded from analysis, assum-
ing that they would be pre-classified as high-risk irrespective of score.
Continuous data were presented as median and interquartile
range. Fisher’s exact test was used for comparisons of categorical
data, including sensitivity and specificity between the derivation and
validation cohorts. Confidence intervals were calculated for both the
derivation and validated datasets using hybrid Wilson/Brown
method [42]. The Newcombe-Wilson test with continuity correction
was used for difference between proportions. A CDR was considered
reproducible if there was no significant difference between either
sensitivity or specificity in the derivation and validation cohorts.
3. Sample size
International data indicate that MDI occurs in between 18 and
25% of FN episodes [7,19]. Sample size estimates were based on vali-
dation of the PICNICC CDR as this was most recently derived and
included individual participant data from six of the CDR included in
this study [2124,27,28]. For validation, 780 episodes of FN, with an
estimated event rate of 18%, were required for 80% power to show
that AUC-ROC of the PICNICC model is  0.7.
Table 1
Definitions used in study.
Definition
Fever A single temperature 38°C
Neutropenia Absolute neutrophil count (ANC)
<1000/mm3.
End of FN episode Afebrile for more than 48 h, recovery
of ANC beyond nadir and antibiotic
cessation
Severely unwell Severe sepsis or septic shock (as per
Goldstein et al.) [15], altered con-
scious state (Glasgow Coma Score
<15 or only responsive to voice or
pain), documented as ‘severely
unwell’ or equivalent in patient
record or either blood pressure or
respiratory rate within the manda-
tory emergency call range [16].
Bacteraemia [17]. A recognised pathogen (including
organisms associated with mucosal
barrier injury in the setting of
mucositis or neutropenia) from1
blood culture set or common com-
mensals from2 blood culture sets
drawn on separate occasions [17].
Microbiologically documented
infection [17]
An infection that was clinically
detectable and microbiologically
proven [17].
Clinically documented infection
[17]
A site of infection that is diagnosed
but its microbiological pathogene-
sis either cannot be proven or is
inaccessible to examination. [17]
Likely bacterial infection [18] Any infection with a microbiologically
documented bacterial cause or that
was clinically documented in cate-
gories typically attributed to bacte-
rial infection, including pneumonia,
skin and soft-tissue infection, osteo-
myelitis or myositis, enterocolitis,
otitis media or externa, sinusitis,
epididymoorchitis, central venous
catheter pocket or tunnel infection,
pharyngitis, perianal abscess or cel-
lulitis, peritonitis, lymphadenitis, or
culture-negative sepsis.
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3.1. Role of funding source
The funding source had no involvement in study design, data col-
lection, analysis or manuscript preparation or approval.
3.2. Ethics
The study had national and site specific Human Research Ethics
Committee approval and informed patient consent was obtained.
4. Results
A total of 2124 episodes of fever or clinical instability in children
with cancer were screened of which 858 FN episodes occurring in
462 patients were included (Figure 1, online supplement). Patient
accrual occurred from 1 December 2016 to 31 January 2018. The
number recruited exceeded the sample size by 10% as recruitment
was delayed at two sites and accrual remained open to enable a mini-
mum of 4 months of data collection per site.
Table 2
Details of clinical decision rules undergoing prospective validation and key differences between derivation and validation datasets.
Rule High risk variables High risk outcome Key differences in derivation and validation
dataset
Rules predicting microbiologically defined infection
PICNICC [8] Weighted variables for malignancy type,
maximum temperature, clinically
unwell, WCC, haemoglobin and AMC
Microbiologically defined infection Developed from IPD meta-analysis from 22 stud-
ies with variable inclusion and exclusion
criteria
Rules predicting adverse outcome
SPOG-AE [21] Applied after 24 h. Total score  9 = high
risk
Adverse outcome defined as a serious medical
complication (death, ICU or other life-threaten-
ing complication) as a result of infection, MDI
and radiologically confirmed pneumonia
-Excluded inpatient onset FN.
-Fever:  38¢5 °C once or 38¢0 °C during 2 h
Score for preceding chemotherapy more
intensive than ALL maintenance =4;
haemoglobin  90=5; WCC < 300
cells/mm3 = 3; platelet <50 G/L=3
-Neutropenia: ANC  500cells/mm3
-Bacteraemia not defined*
Hakim [22] Total score  24 = high risk Proven invasive bacterial infection defined as
isolation of a pathogen from a sterile body site
or as proven by histology or culture-negative
sepsis defined as a systemic response to a pos-
sible infection because of hemodynamic insta-
bility, focal or multiple organ involvement or
altered mental status or lethargy
-Excluded inpatient onset FN
Score for cancer diagnosis: AML=20, ALL/
lymphoma = 7, solids = 0 points; Seri-
ously unwell** = 14 points; tempera-
ture 39 °C = 11 points; ANC <100
cells/mm3 = 10 points
Bacteraemia defined as a recognized pathogen
cultured from one or more blood cultures or
common commensals cultured from two or
more blood cultures
-Fever: 38¢3 °C or  38¢0 °C for 1 h
Alexander [23] Any of following = high risk Adverse outcome defined as identification of a
pathogen or where there was a serious medical
complication or death
-Excluded inpatient onset FN.
AML, Burkitt lymphoma, ALL in induc-
tion, progressive or relapsed disease;
Hypotension, tachypnea/hypoxia 94%;
new CXR changes; altered mental sta-
tus; severe mucositis; vomiting or
abdominal pain; focal infection; other
clinical reason for in-patient treatment
-Fever: >38¢5 °C at presentation or within 6h
-Neutropenia: ANC  500cells/mm3
-Bacteraemia,* serious medical complication,*
hypotension*** and focal infection# not defined
Klaassen [24] AMC < 100 cells/mm3 Significant bacterial infection defined as blood
or urine culture positive for bacteria, interstitial
or lobar consolidation on CXR, or unexpected
death from infection (patient not palliative)
-Excluded comorbidity on presentation inc.
severe mucositis and pneumonia
-Fever: > 38¢5 °C once or > 38¢0 °C or within 12h
Rules predicting bacteraemia
SPOG-bacteraemia [28] Applied after 24 h Bacteraemia defined as at least 1x positive blood
culture
-Excluded inpatient onset FN.
Score for shaking or chills = 5; Hb
90 = 3; platelet <50 G/L = 3; Other
need for inpatient care = 3
-Fever:  38¢5 °C once or  38¢0 °C for 2h
-Neutropenia: ANC  500cells/mm3
-Definition of bacteraemia different
Ammann [27] High risk: any of temperature >39¢7 °C,
comorbidity requiring inpatient care,
WCC1000 cells/mm3, not in
remission
Bacteraemia defined as at least 1x positive blood
culture
-As for SPOG bacteraemia CDR
Baorto [25] AMC<155 cells/mm3 Bacteraemia (not defined)* -Excluded age<1y
-Neutropenia  ANC < 500cells/mm3
Rackoff [26] High risk: AMC < 100 cells/m3 and tem-
perature 39 °C
Bacteraemia defined as a positive blood culture -Excluded inpatient onset FN.
Low risk = AMC  100 cells/mm3; inter-
mediate risk = AMC < 100 cells/mm3
and temperature <39 °C
-Fever:  38¢5 °C once or  38¢0 °C 3x within 24h
-Neutropenia: ANC < 500cells/mm3
-Definition of bacteraemia different
PICNICC, Predicting Infectious ComplicatioNs In Children with Cancer; WCC, white cell count; AMC, absolute monocyte count; IPD, individual participant data; SPOG, Swiss Paediatric
Oncology Group; AE, adverse event; ANC, absolute neutrophil count; ALL, acute lymphoblastic leukaemia; ICU, intensive care unit; MDI, microbiologically defined infection; AML,
acute myeloid leukaemia; HSCT, haematopoietic stem cell transplant; SMC, seriousmedical complication; ICU, intensive care unit; PCR, polymerase chain reaction.
* international consensus definition used for validation.52
** defined as severe sepsis or septic shock (as per Goldstein et al.), 15 altered conscious state (Glasgow Coma Score <15 or only responsive to voice or pain), documented as
‘severely unwell’ or equivalent in the patient record or either the blood pressure or respiratory rate in the mandatory emergency call range.16
*** Hypotension defined according to VICTOR chart.16
# Focal infection includes defined as upper respiratory tract infection (URTI), lower respiratory tract infection (LRTI), anorectal infection or central venous catheter (CVC)
infection.
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Demographic data is available in Table 3. The primary cause of
fever was bacteraemia in 111 (12¢9%) episodes, non-bacteraemia MDI
in 185 (21¢6%), clinically defined infection in 80 (9¢3%) and fever of
unknown cause in 482 (56¢2%). A viral upper respiratory tract infec-
tion was the most common non-bacteraemia MDI (n = 101) followed
by infective enterocolitis (n = 39) and bacterial urinary tract infection
(n = 13). A likely bacterial infection occurred in 198 (23¢1%) episodes
(proven in 167 and probable in 31).
Overall, severe sepsis occurred in 13 (1¢5%) (4 h in 7 and >4 h in
6), ICU admission in 24 (2¢8%) (median time to admission 9¢2 h, IQR
4¢5157¢6 h) and 30-day all-cause mortality in four (0¢9%). There
were no deaths attributed to infection.
4.1. Validation at presentation
Eight rules exhibited reproducibility (Table 4). Four showed this
both in both sensitivity and specificity; PICNICC, Rackoff, Baorto and
SPOG-bacteraemia CDRs. In the remaining, reproducibility was
observed for sensitivity only in the Klaassen and Ammann CDRs and
for specificity only in the SPOG-adverse event (AE) and Alexander
CDRs. For the prediction of ‘likely bacterial infection,’ sensitivity
improved for four of the reproducible CDRs: PICNICC, SPOG-AE, Alex-
ander and Klaassen (Table 5).
When restricted to outpatient onset FN (n = 689), there was no
significant difference in the sensitivity and specificity analyses when
compared to the full FN cohort (n = 858) for all CDRs except the Alex-
ander (sensitivity and specificity) and the Hakim rules (specificity
only) (online supplement).
Across the nine CDRs the AUC-ROC ranged from 0¢51 to 0¢69. The
AUC-ROC improved for three CDRs for the prediction of ‘likely bacte-
rial infection’ (PICNICC, SPOG-AE, Alexander) (Table 5). Similarly, for
prediction of bacteraemia alone, the AUC-ROC improved for the PIC-
NICC CDR.
The recalibrated-PICNICC rule had a scaled Briers score of 27%
(95% CI 2530%) and calibration slope of 0¢23 (95% CI 0¢040¢65).
Calculation of the odds ratios for each of the individual PICNICC varia-
bles indicated tumour type (acute myeloid leukaemia, Ewing’s sar-
coma, osteosarcoma, Hodgkin lymphoma) and temperature were the
strongest predictors of MDI (online supplement). When the first, or
subsequent, episodes were assessed separately, there was no signifi-
cant differences in the score (p = 0¢65) or AUC-ROC for MDI (p = 0¢63).
Similarly, when the effect of individual sites was assessed, there
was no moderator effect. For prediction of bacteraemia alone, the
AUC-ROC improved to 0.70 (95% CI 0¢630¢75) (online supplement).
Two rules (SPOG-AE and SPOG-bacteraemia) were designed to be
applied after a period of overnight observation. Applying these at
presentation is associated with reduced sensitivity: from 72% to 55%
(95% CI 5061%) for SPOG-AE and from 100% to 92% (95% CI 8596%)
for SPOG-bacteraemia. For the Rackoff CDR which stratifies patients
into three groups, the proportion of episodes with bacteraemia in the
low risk group was 4¢8%, increasing to 12% in the intermediate and
23% in the high-risk groups (p<0¢05).
4.2. Validation at day 2
Day 2 assessment occurred a median 18¢6 h after FN presentation
(IQR 14¢723¢8 h). Using SPOG methodology, the adjusted sensitivity
improved for all nine CDRs (Table 6) [21].
The clinical utility of the PICNICC CDR at day 2 was also deter-
mined using variables collected on day 2. Repeat blood samples were
not taken in 109 episodes and in a further 112 episodes, an MDI,
severe sepsis or ICU admission prior to day 2 assessment was docu-
mented and were excluded. In episodes with missing and non-
missing bloods, there was no significant difference in the proportion
with an MDI (25¢7% vs 21%, p = 0¢26) and bacteraemia (7¢3% vs 13¢8%,
p = 0¢07). Using this methodology, the sensitivity, specificity, PPV and
NPV of the PICNICC rule in the remaining 637 episodes was 93¢5%
(95% CI 88¢5%96¢4%), 12¢6% (95% CI 9¢915¢9%), 25¢4% (95% CI
22¢029¢2%) and 85¢9% (95% CI 76¢092¢2%), respectively, and 71
(11¢1%) episodes were identified on day 2 as low risk.
4.3. Other clinically significant events
Details of the missed outcomes in episodes classified as low-risk
are available in Table 6 and the online supplement (Table 4). In five
rules, between one and five low-risk episodes required ICU-level
care. In the SPOG-bacteraemia and SPOG-AE rules, these admissions
occurred before day 2 assessment, and in the Rackoff rule three out
of five occurred before day 2 assessment. For the missed bacteraemia
episodes, the median time to initial pathogen identification was
31¢2 h (IQR 24¢042¢8 h)
5. Discussion
This is the largest, multicentre prospective validation study of
paediatric FN CDRs published to date. Each of the nine CDRs were rig-
orously assessed in a ‘real-world’ context using contemporary
Table 3
Demographic and outcome data.
n = 858
Median age, years (IQR) 5.8 (3¢510¢7)
Female, n (%) 415 (48¢4)
Aboriginal and/or Torres Strait Islander, n (%) 37 (4¢3)
Acute leukaemia, n (%) 449 (52¢3)
-Acute lymphoblastic leukaemia 375
-Acute myeloid leukaemia 67
-Other 7
Lymphoma, n (%) 66 (7¢7)
-Non-hodgkin lymphoma (excl. Burkitts) 36
-Burkitts lymphoma 19
-Hodgkin lymphoma 11
Solid tumour, n (%) 343 (40¢0)
-Ewing sarcoma 70
-Osteosarcoma 51
-Neuroblastoma 48
-Rhabdomyosarcoma 41
-Medulloblastoma 37
-Wilm’s tumour 19
-Clear cell sarcoma (kidney) 15
-Other brain tumours 37
-Other solid tumour 25
Relapse/refractory disease, n (%):
-Leukaemia/lymphoma 102 (19¢8)
-Solid tumour 31 (9¢0)
-Allogeneic HSCT > 3 months prior, n (%) 5 (0¢6)
-Autologous, n (%) 18 (2¢1)
Central venous catheter in situ, n (%) 845 (98.5)*
-Implanted Port 454
-Tunnelled external catheter 358
-Peripherally inserted central catheter 32
-Non-tunnelled external catheter 5
Prophylaxis, n (%)
-Pneumocystis jirovecii pneumonia (PJP) 830 (96¢7)
-Antifungal 290 (33¢8)
-Antiviral 72 (8¢4)
-Antibacterial (excl. for PJP) 22 (2¢6)
Location of FN onset, n (%)
-Outpatient 581 (67.7)
-Inpatient ward 169 (19.7)
-Day chemotherapy/day medical 87 (10.1)
-Hospital in the home 21 (2.5)
Primary cause of FN, n (%)
-Bacteraemia 111 (12.9)
-Other microbiologically defined infection 185 (21.6)
-Clinically defined infection 80 (9.3)
-Fever without focus 482 (56.2)
IQR, interquartile range; excl, excluding; FN, febrile neutropenia.
* 4 patients had 2 CVCs.
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Table 4
Sensitivity, specificity, positive predictive value and negative predictive value of derivation study (d) and prospective validation (Pv) cohort at febrile neutropenia presentation.
Rule Epi-sodes Out-come, n (%) Low risk, n (%) AUC (95% CI) Sensitivity Specificity PPV,% (95% CI) NPV,% (95% CI) LR
% (95% CI) Dif from deriv.% (p value) % (95% CI) Dif from deriv.% (p value)
Rules predicting microbiologically defined infection
d-PICNICC [8] 909 236 (26¢0) 163 (17¢9)  91.5 (87¢394¢4)  21¢2 (18.324¢5)  29 (25¢832¢2) 87¢7 (81¢891¢9) 1¢2
Pv-PICNICC 858 296 (34¢5) 155 (18¢1) 0¢56 (0¢530¢60) 87¢2 (82¢990¢5) 4¢3 (0¢12) 20¢8 (17¢724¢4) 0¢4 (0¢89) 36¢7 (33¢240¢3) 75¢5 (68¢281¢6) 1¢1
Rules predicting adverse outcome
d-SPOG AE [21] 423 122 (28¢2) 165 (39) NA 91¢8* (85¢695¢5)  51¢5 (45¢957¢1)  43¢3 (37¢549¢5) 93¢9 (89¢296¢7) 1¢9
Pv-SPOG AE 858 320 (37¢3) 329 (38¢3) 0¢54 (0¢510¢58) 72¢2* (67¢076¢8) 19¢6 (<0¢001) 44¢6 (40¢548¢8) 6¢9 (0¢07) 43¢7 (39¢547¢9) 73¢0 (67¢977¢5) 1¢3
d-Hakim [22] 323 47 (14¢6) 223 (69) NA 74¢5 (60¢584¢7)  76¢4 (71¢181¢1)  35¢0 (26¢444¢7) 94¢6 (90¢896¢9) 3¢2
Pv-Hakim 858 151 (17¢6) 693 (80¢8) 0.69 (0¢640¢73) 41¢7 (34¢249¢7) 32¢8 (<0¢001) 85¢6 (82¢888¢0) 9¢1 (<0¢001) 38¢2 (31¢145¢8) 87¢3 (84¢689¢6) 2¢9
d-Alexander [23] 104 22 (21¢2) 55 (53) NA 90¢9 (72¢298¢4)  64¢6 (53¢874¢1)  40¢8 (28¢254¢8) 96¢4 (87¢799¢4) 2¢6
Pv-Alexander 858 306 (35¢7) 354 (41¢3) 0¢51 (0¢470¢55) 63¢7 (58¢268¢9) 27.2 (<0.01) 44¢0 (39¢948¢2) 20¢6 (<0¢001) 38¢7 (34¢543¢0) 68¢6 (63¢673¢2) 1¢1
d-Klaassen [24] 227 43 (18¢9) 83 (36¢6) NA 83¢7 (7091¢9)  41¢5 (34¢648¢8)  25¢3 (18¢832¢9) 91¢6 (83¢695¢9) 1¢4
Pv-Klaassen 858 135 (15¢7) 207 (24¢1) 0¢59 (0¢550¢63) 85¢2 (78¢290¢2) 1¢5 (0¢81) 25¢9 (22¢829¢2) 15¢7 (<0¢001) 17¢7 (14¢920¢8) 90¢3 (85¢693¢7) 1¢2
Rules predicting bacteraemia
d-SPOG bacteraemia [28] 423 67 (15¢8) 54 (12¢8) NA 100* (94¢6100)  15¢2 (11.819.3)  18¢2 (14¢622¢4) 100 (93.4100) 1¢2
Pv-SPOG bacteraemia 858 111 (12¢9) 133 (15¢5) 0¢63 (0¢580¢69) 94¢6* (88¢797¢5) 5¢4 (0¢8) 17¢1 (14¢620¢0) 1¢9 (0¢44) 14.5 (12.117.3) 95.5 (90.697.9) 1¢1
d-Ammann [27] 348 85 (24) 100 (28¢7) NA 95¢3 (88¢598¢2)  36¢5 (30¢942¢5)  3¢7 (27¢138¢7) 96¢0 (90.298.4) 1¢5
Pv-Ammann 858 111 (12¢9) 139 (16¢2) 0¢57 (0¢540¢59) 95¢5 (89¢998¢1) 0¢2 (>0¢99) 17¢9 (15¢420¢9) 18¢6 (<0¢001) 14¢7 (12¢317¢5) 96¢4 (91.998.5) 1¢2
d-Baorto [25] 1171 189 (16¢1) 164 (14) NA 94¢7 (90¢597¢1) NA 15¢7 (13¢518¢1) NA 17¢8 (15¢520¢3) 93¢9 (89¢196¢7) 1¢1
Pv-Baorto 858 111 (12¢9) 148 (17¢2) 0¢59 (0¢560¢62) 93¢7 (87¢6- 96¢9) 1.0 (0.80) 18¢9 (16¢221¢8) 3¢2 (0¢08) 14¢6 (12¢217¢4) 95¢3 (90¢597¢7) 1¢2
d-Rackoff [26] 115 24 (20¢9) 94 (81¢7) NA 41¢7 (24¢561¢2)  87¢9 (79¢693¢1)  47¢6 (28¢367¢6) 85¢1 (76¢590¢9) 3¢5
Pv-Rackoff** 858 111 (12¢9) 691 (80¢5) 0¢63 (0¢590¢69) 35¢1 (26¢944¢4) 6¢5 (0¢64) 82¢9 (80¢085¢4) 5¢0 (0¢30) 23¢4 (17¢630¢3) 89¢6 (87¢191.6) 2¢1
Pv-Rackoff*** 858 111 (12¢9) 207 (24¢1)  91¢0 (84¢295¢0) NA 26¢4 (23¢329¢7) NA 15¢5 (12¢918¢5) 95¢2 (91¢397¢4) 1¢2
d, derivation study; Pv, prospective validation; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; Dif from deriv, difference from derivation study.
* includes episodes with adverse event known at reassessment.
** intermediate and low risk combined into a single low-risk group.
*** intermediate and high-risk combined into a single high-risk group.
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definitions and detailed information is available on all clinically-
significant infections and adverse events. The PICNICC, Rackoff,
Baorto and SPOG-bacteraemia CDRs, were reproducible with overlap-
ping sensitivity and specificity in the derivation and validation
datasets [8,25,26,28]. Only one CDR (Hakim) did not exhibit repro-
ducibility in this population, in keeping with an earlier study [22,43].
Overall the discriminatory ability (as measured by AUC-ROC) and the
likelihood of predicting the outcomes defined in the original deriva-
tion studies (measured by the likelihood ratio), for each CDR assessed
was moderate, at best. However, across all CDRs designed to be
implemented at FN presentation, the sensitivity improved at day 2
assessment after taking into consideration outcomes known at that
time [8,22-27]. Notably, for three rules predicting a composite outcome
that included all MDIs, sensitivity, discriminatory ability and likelihood
ratio also improved for prediction of ‘likely bacterial infection’ [8,21,23].
Although we have demonstrated that most CDRs exhibited repro-
ducibility as evidenced by overlapping sensitivity or specificity, not
all are suitable for inclusion in clinical FN pathways that support
reduced-intensity treatment. In the classic trade-off between sensi-
tivity and specificity, rules that had high (>85%) sensitivity in pre-
dicting outcomes resulted in very few patients being classified as low
risk [25,27,28]. While this sensitivity may sit more comfortably with
clinicians and patients, it is difficult to justify the time and effort
required for successful implementation of a low-risk program incor-
porating rules which identify less than 20% of episodes as low risk
[44]. Looking towards the reproducible rules with a higher propor-
tion of episodes allocated as low-risk (i.e. SPOG-AE, Alexander and
Rackoff), albeit with a lower sensitivity, factoring in additional safe
guards such as a period of overnight observation may make these
more palatable [21,23,26]. Such a pragmatic approach has been suc-
cessfully described in the adult FN population where patients strati-
fied as low-risk must also have stable underlying disease, no active
infection or medical complication requiring in-hospital care and suit-
ably resourced follow up before being eligible for home-based care
[45].
Various pathways for reduced-intensity treatment of children
with low-risk FN have been explored, ranging from entirely home-
based management to early discharge after a period of in-hospital
observation with either oral or intravenous antibiotics [4,46]. While
these options have been shown to be safe in randomised trials, stud-
ies using more stringent risk assessment demonstrate lower rates of
treatment failure [4]. The type of reduced-intensity treatment should
be tailored to the patient and hospital and be accompanied by appro-
priate patient and clinician education [47]. Similarly, decisions about
Table 5
Sensitivity, specificity, positive predictive value and negative predictive value of prospective validation cohort at febrile neutropenia presentation to
predict ‘likely bacterial infection.’
Low-risk, n (%) AUC-ROC (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR
PICNICC 155 (18¢1) 0¢66 (0¢620.71) 90¢9 (86¢194¢2) 20¢8 (17¢824¢0) 26¢6 (22¢529¢0) 88¢4 (82¢492¢5) 1¢2
SPOG-AE 329 (38¢3) 0¢61 (0¢570¢65) 75¢8 (69¢381¢2) 47¢9 (44¢151¢7) 30¢4 (26¢534¢6) 86¢8 (82¢989¢9) 1¢5
Hakim 693 (80¢8) 0¢60 (0¢560¢64) 29¢3 (23¢436¢0) 83¢8 (80¢886¢4) 35¢2 (28¢342¢7) 79¢8 (76¢782¢6) 1¢8
Alexander 354 (41¢3) 0¢57 (0¢530¢61) 69¢7 (63¢075¢7) 44¢6 (40¢848¢4) 27¢4 (23¢731¢4) 83¢1 (78¢886¢6) 1¢3
Klaassen 207 (24¢1) 0¢57 (0¢550¢60) 87¢4 (82¢091¢3) 27¢6 (24¢331¢1) 26¢6 (23¢330¢1) 87¢9 (82¢891¢7) 1¢2
SPOG-bact 134 (15¢6) 0¢60 (0¢560¢65) 90¢9 (86¢194¢2) 17¢6 (14¢920¢7) 24¢9 (21¢928¢1) 86¢6 (79¢891¢3) 1¢1
Ammann 139 (16¢2) 0¢56 (0¢540¢58) 92¢9 (88¢595¢7) 18¢9 (16¢122¢1) 25¢6 (22¢528¢9) 89¢9 (83¢893¢9) 1¢2
Baorto 148 (17¢2) 0¢55 (0¢520¢57) 89¢9 (84¢993¢4) 19¢4 (15¢622¢6) 25¢1 (22¢028¢4) 86¢5 (80¢191¢1) 1¢1
Rackoff** 691 (80¢5) 0¢60 (0¢550¢64) 27¢3 (21¢633¢9) 82¢9 (79¢885¢6) 32¢3 (25¢739¢8) 79¢2 (76¢082¢0) 1¢6
Rackoff*** 207 (24¢1)  87¢4 (82¢091¢3) 27.6 (24¢331¢1) 26¢6 (23¢330¢1) 87¢9 (82¢891¢7) 1¢2
AUC-ROC is area under receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.
** intermediate and low risk combined into a single low-risk group.
*** intermediate and high-risk combined into a single high-risk group.
Table 6
Adjusted sensitivity of each clinical decision rule taking into consideration of outcomes known at Day 2 reassessment and details of missed outcomes for episodes classified as
low risk (outpatient onset FN only, n = 689). Details of missed bacteraemia episodes after Day 2 assessment are available in online supplement.
Rule (number
low risk)
Adjusted Day
2 Se. (95% CI)^
Missed outcomes in low-risk group Other outcomes in low-risk group
Missed
outcomes,
n (%)
Median time to
diagnosis, h (IQR)*
Known at
Day 2,
n (%)
Bacteraemia n (%) ICU admission,
n (%)
Late onset
severe
sepsis,
n (%)
30 day
mortality,
n (%)
Median LOS,
days (IQR)
All >Day2
Rules predicting microbiologically defined infection
PICNICC [8] (140) 90¢7 (86¢393¢8) 33 (23¢6) 42.3 (19¢252¢4) 11 (33¢3) 7 (5¢0) 5 (3¢6) 0 0 0 3¢0 (2¢14¢7)
Rules predicting adverse outcome
SPOG-AE [21] (309) NA 114 (36¢9)** 31¢9 (12¢953¢4) 41 (36¢0) 22 (7¢1)** 17 (5¢5) 1*** (0¢3) 0 2 (0¢6) 3¢9 (2¢57¢0)
Hakim [22] (589) 68¢0 (58¢476¢2) 65 (11¢0) 23¢7 (17¢139¢0) 32 (49¢2) 49 (8¢3) 28 (4¢8) 2*** (0¢3) 1*** (0¢2) 2 (0¢3) 4¢1 (2¢77¢1)
Alexander [23]
(354)
69¢0 (62¢974¢6) 111 (31¢4) 37¢6 (15¢762¢2) 37 (33¢3) 29 (8¢2) 13 (3¢7) 2 (0¢6) 2 (0¢6) 0 3¢9 (2¢76¢8)
Klaassen [24] (187) 90¢7 (83¢395¢0) 18 (9¢6) 36¢6 (8¢959¢3) 9 (50) 8 (4¢3) 4 (2¢1) 0 0 0 2¢9 (2¢04¢1)
Rules predicting bacteraemia
SPOG-bact [28]
(137)
NA 9 (6¢6)** 27¢8 (17¢042¢4) 3 (33¢3) 9 (6¢6) 6 (4¢4) 1*** 0 0 4¢5 (2¢66¢8)
Ammann [27] (139) 96¢0 (88¢998¢9) 5 (3¢6) 26¢6 (5¢946¢1) 2 (40) 5 (3¢6) 3 (2¢2) 0 0 0 2¢9 (2¢04¢2)
Baorto [25] (135) 96¢0 (88¢998¢9) 6 (4¢4) 31¢5 (8¢566¢6) 3 (50) 6 (4¢4) 3 (2¢2) 0 0 0 2¢8 (2¢03¢7)
Rackoff [26]
(low & int 547)
67¢7 (55¢476¢3) 45 (8¢2) 23¢6 (16¢937¢1) 20 (44¢4) 45 (8¢2) 25 (4¢6) 5 (0¢9)# 1 (0¢2)#,*** 2 (0¢4)# 4¢2 (2¢77¢2)
Se, sensitivity; h, hour; IQR, interquartile range; ICU, intensive care unit; LOS, length of stay; AE, adverse event.
^ using SPOG methodology.
* For composite outcomes the time to diagnosis of first outcome was used.
** data presented for missed episodes at FN presentation.
*** Outcome known prior to day 2 assessment.
# all missed episodes were classified as intermediate risk and ICU admission known prior to day 2 assessment in 3 out of 5.
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which validated CDR to incorporate into low-risk FN pathways
require site-specific feasibility assessments. Factors such as timely
manual white cell count differentials for accurate monocyte counts (i.
e. Klaassen, Baorto, Rackoff CDRs) and access to electronic algorithms
for calculation of complicated scoring systems (i.e. PICNICC CDR)
require careful consideration in the implementation phase.
There is no international consensus as to the most important out-
come to predict in children presenting with FN. Given that bacteria
accounts for a significant proportion of infectious causes of FN and
underscores the rationale for early introduction of broad-spectrum
antibiotics, focusing our efforts on predicting bacterial infections may
be the most sensible approach [40]. Three of the CDRs validated in
this study include all MDI’s as part of a composite outcome and there-
fore provide equal weight to bacteraemia and a viral upper respira-
tory illness [8,21,23]. Removing some of the ‘background noise’ of
these viral infections, which do not require antibiotics, improves the
performance of these rules and suggests that all MDIs may not be the
most appropriate outcome to predict at FN onset.
Our study is unique as it provides substantial detail on all missed
clinically significant outcomes. Reassuringly, the rate of missed
severe sepsis or ICU admission was low, with the latter being known
by day 2 assessment in three out of five CDRs [21,22,28]. Although
the overall low number of these adverse outcomes may be influenced
by in-hospital management with intravenous antibiotics, our rates
are in keeping with studies of oral and home-based FN management
strategies [4].
For the SPOG-AE and SPOG-bacteraemia CDRs, both designed to
be implemented at Day 2, the sensitivity for prediction of adverse
event or bacteraemia was considerably lower if applied at presenta-
tion [21,28]. Centres adopting either of these rules must be aware of
this and ensure patients identified as low risk have an appropriate
period of observation prior to transfer to home-based care. The Rack-
off rule is also unique in that it stratifies patients into three groups:
low, intermediate and high. With a sensitivity of 91% and NPV of 95%
when the low-risk group is considered separately, implementation of
a low-risk program utilising this rule could facilitate early discharge
of these patients with consideration for early discharge in the inter-
mediate group provided additional safety criteria are fulfilled.
Across all sites the number of children with cancer presenting to
hospital with non-neutropenic fever (NNF) exceeded the number
with FN. This burden is previously unrecognised as reflected by the
paucity of NNF studies and the absence of guidelines [48]. To date,
only one risk-prediction rule has been derived in children with NNF .
[49]. Unlike FN CDRs, a higher ANC was associated with an increased
risk of infection, highlighting that rules derived in children with FN
are not applicable when the ANC >1.0.
This is the first prospective, multicentre validation of the PICNICC
CDR and is the result of a national multidisciplinary collaboration. In
addition to the PICNICC rule, the study was sufficiently powered to
validate all eight CDRs. To replicate real life, we permitted multiple
episodes per patient and there was no significant differences
between the discriminatory values in first of subsequently captured
episodes. A potential limitation is that inclusion criteria of all deriva-
tion studies was not replicated. However, the impact is likely to be
small as a previous validation of six CDRs included in this study found
no significant difference in sensitivity and specificity when different
criteria, including both fever and neutropenia definitions, were used
[43]. While we have shown there was no significant difference in
CDR performance across study sites, these results may not be gener-
alisable outside of both Australia and the original countries (predomi-
nantly European and North American) where they were derived.
Finally, as few patients (<3%) received antibacterial prophylaxis
results may not be generalisable to patients receiving fluoroquino-
lones and who may be at risk of breakthrough infections with antibi-
otic-resistant organisms.
Currently no paediatric FN CDR can perfectly predict infections or
adverse outcomes in children presenting with FN. Given that there
have been at least 27 attempts to derive such a rule, this quest for per-
fection is unlikely to be achieved using currently available clinical,
radiological and biochemical parameters. While novel biomarkers or
harnessing the research capabilities of electronic medical records may
provide some hope in the future, clinicians could turn towards existing
rules and explore ways to safely incorporate these into low-risk FN
programs. Consideration should also be given to recalibration of these
rules to refine their predictive ability, however this would require fur-
ther revalidation. For rules such as PICNICC, SPOG-AE or SPOG-bacter-
aemia, provision of actual risk scores or percentages may also be of
benefit, although further research is required to determine how this
may impact patient- and clinician-level decision making.
Our study provides a contemporary and accurate understanding of
nine CDRs in the Australian population. Results will inform formal imple-
mentation studies that incorporate clinical, economic and quality of life
evaluation of low-risk FN management strategies. Although no single
CDR performance was superior, we believe a number of the validated
rules could be incorporated into practice, depending on the desired
treatment strategy. For entirely home-based treatment, CDRs with the
highest sensitivity and NPV should be used, while CDRs with lower sen-
sitivity could be used to select suitable patients for early (<24 h) transfer
to home-based care. However, irrespective of the approach and the CDR
that is used, appropriate safe guards, together with a structured home-
based program incorporating clear recommendations for readmission,
together with rigorous evaluation, remain paramount.
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